In all fairness, supply of the drug has been an issue and that would explain the small trial size. Still, you have a point. Perhaps there needs to be more safety study.
Neurotrope Bioscience to Present at the 19th Annual
BIO CEO & Investor Conference 2017
NEW YORK, February 7, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP / NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases including Alzheimer's disease, announces that Susanne Wilke PhD, Neurotrope’s Chief Executive Officer, and Dr. Daniel Alkon, President and Chief Scientific Officer, are scheduled to present at the 2017 BIO CEO & Investor Conference being held February 13-14, 2017 at the Waldorf Astoria Hotel in New York City.
The Company’s presentation will take place on Monday, February 13th, 2017 at 10:30am EST in the Conrad room during the conference's CNS/Neurological Track. In addition, any investors attending the conference that wish to meet with Neurotrope’s management can also contact our Director of Communications, Jeffrey Benison.
Neurotrope will announce topline efficacy results for its Phase 2, randomized, double blind, placebo controlled trial in 148 patients with moderate to severe Alzheimer's patients this coming April. The Company's lead drug, bryostatin-1, has demonstrated in animal models, efficacy for restorative synaptogenesis, prevention of neuronal death, and anti-amyloid, anti-tau metabolism via the activation of PKC epsilon. The restorative therapeutic potential of bryostatin-1 and bryostatin-like activators, may be fundamental to a number of neuro-degenerative pathways and neurologic indications including AD, Fragile X syndrome (FXS), stroke, traumatic brain injury (TBI), and depression.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded biotech companies. The conference’s mission is to support industry-wide success, and to present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's disease and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by bryostatin, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.
Neurotrope is conducting a Phase 2 trial of bryostatin in the treatment of moderate to severe Alzheimer's disease, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Sydrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.
All the approved drugs on the market show improvement at 3 months, even 6 months.
Blu, the approved drugs on the market show slowing of progression of symptoms, not improvement. Furthermore, Bryostatin is not a "statin" as you imply. It is not related to the drugs intended to lower cholesterol.
News 
Market Data 
Discover 
